Obviously, an unblinded trial design (also known as an open-label trial) represents a particularly high-risk approach when the outcome involves a subjective assessment by either the patient or the physician.

FORBES: Clinical Trial Advice For Investors From Two Pros

The study was a multinational, single-arm, open-label, 78 week trial that was recently published in the November 2, 2012 online version of the Lancet.

FORBES: FDA Approves Lomitapide For Homozygous Familial Hypercholesterolemia